compound 17 [PMID: 33655614]   Click here for help

GtoPdb Ligand ID: 11520

Compound class: Synthetic organic
Comment: Compound 17 is a SARS‐CoV‐2 Mpro inhibitor [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 54.98
Molecular weight 306
XLogP 3.68
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Clc1cncc(c1)OC(=O)c1[nH]c2c(c1)cc(cc2)Cl
Isomeric SMILES Clc1cncc(c1)OC(=O)c1[nH]c2c(c1)cc(cc2)Cl
InChI InChI=1S/C14H8Cl2N2O2/c15-9-1-2-12-8(3-9)4-13(18-12)14(19)20-11-5-10(16)6-17-7-11/h1-7,18H
InChI Key WGTDTRRECQYDFW-UHFFFAOYSA-N
References
1. Botyanszki J, Catalano G, Chong PY, Dickson H, Jin Q, Leivers A, Maynard A, Liao X, Miller J, Shotwell JB et al.. (2018)
Compounds that inhibit 3c and 3cl proteases and methods of use thereof.
Patent number: WO2018042343A2. Assignee: Glaxosmithkline Intellectual Property (No.2) Limited. Priority date: 30/08/2016. Publication date: 08/03/2018.
2. Breidenbach J, Lemke C, Pillaiyar T, Schäkel L, Al Hamwi G, Diett M, Gedschold R, Geiger N, Lopez V, Mirza S et al.. (2021)
Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
Angew Chem Int Ed Engl, 60 (18): 10423-10429. [PMID:33655614]
3. Vankadara S, Wong YX, Liu B, See YY, Tan LH, Tan QW, Wang G, Karuna R, Guo X, Tan ST et al.. (2021)
A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
Bioorg Med Chem Lett, 48: 128263. [PMID:34271072]